Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2024
Reporting Period: Fourth quarter and fiscal year ended December 31, 2023
This filing serves as a notification that the Company issued a press release and investor presentations regarding its financial results for the period ended December 31, 2023. The detailed financial data is contained in the attached exhibits (Exhibit 99.1, 99.2, and 99.3) and is not embedded directly within the text of this Form 8-K.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being disclosed in the press release (Exhibit 99.1) and investor presentations (Exhibits 99.2 and 99.3) attached to the filing.
Material Changes
No specific material changes in financial condition or operations are detailed in the body of this Form 8-K. The filing indicates that the Company has announced results for the fourth quarter and full year 2023, but the magnitude of changes versus prior periods is not stated in this summary document.
Guidance, Outlook, and Risks
- Disclosure Channels: The Company utilizes SEC filings, its investor relations website (https://ir.recursion.com/), press releases, conference calls, and social media to communicate material information.
- Legal Disclaimer: Information furnished under Item 2.02 and Item 7.01, including the attached exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly incorporated by reference.
- Outlook: Specific forward-looking guidance or management commentary is contained within the attached exhibits and is not summarized in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2023 financial results, including revenue, net loss, and cash position.
- Examine Exhibit 99.2 (Investor Presentation) for updated strategic outlook, pipeline progress, and capital allocation plans.
- Consult Exhibit 99.3 (Earnings Call Presentation) for management's detailed commentary on operational highlights and challenges.
- Verify the Company's status as an emerging growth company and any related accounting election disclosures in the full filing.